Amgen Blasts Sandoz's En Banc Bid In Enbrel Patent Fight
An Amgen unit urged the Federal Circuit on Wednesday to reject an en banc rehearing petition from Sandoz in their patent fight over the blockbuster biologic Enbrel, saying Sandoz is weaving a...To view the full article, register now.
Already a subscriber? Click here to view full article